Enovix has seen its share price fall sharply over recent years, even as the business puts more emphasis on supplying batteries for drones and defense customers. With the stock now trading around US$1.60, the key issue for you is whether that price is sensible when set against the company’s sales profile.
The issue now is whether Enovix’s current share price is adequately backed by its sales when judged against the Fair Ratio benchmark.
If you want more context around Enovix and this kind of sharp drawdown meets sales-story setup, it can help to compare it with our screener containing 19 high quality undiscovered gems.
For Enovix, P/S is the cleaner yardstick because the business is still loss making and earnings based ratios are less useful. The stock trades on a P/S of 8.7x, compared with an Electrical industry average of about 1.9x and a peer group closer to 8.3x. This means buyers today are paying a relatively rich tag for each dollar of current revenue.
The Fair Ratio, which adjusts for Enovix’s growth prospects, margins, size and risk profile, sits below that headline multiple, so the shares screen as overvalued on this framework. Because the South Korea expansion and fresh defense and drone orders have pushed expectations higher, the current P/S reflects a significant degree of confidence in future execution and leaves less room for disappointment. That gap between what the Fair Ratio suggests and what the market is paying is what you need to weigh before deciding whether the premium is worth it for this story. Explore the numbers behind Enovix's P/S valuation.
Narratives for Enovix pick up where this valuation puzzle leaves off and spell out which assumptions on growth, margins and eventual earnings would need to hold for the stock to be worth materially more or less than today’s price on Simply Wall St’s Community page. Each scenario ties a fair value range to a specific mix of potential catalysts and key risks so you can track over time which version of Enovix’s future is taking shape.
One of the top narratives on Enovix: 84% undervalued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"The main thing that has to go right is Enovix successfully scaling high volume, cost efficient manufacturing in Malaysia and South Korea while improving yields and reducing losses..."
Discover why this Narrative puts Enovix at 84% undervalued.
Before you lean too heavily on the current valuation story, it is worth knowing that Simply Wall St’s checks have highlighted specific areas of concern that could change how you judge the risk profile. Take a closer look at 2 warning signs (1 major) before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com